

## Fact Sheet

ViroPharma Incorporated  
730 Stockton Drive, Exton, PA 19341  
Phone: (610) 458-7300, Fax: (610) 458-7380  
Website: <http://www.viopharma.com>

### Senior Management

**Vincent J. Milano**; President and Chief Executive Officer  
**Colin Broom, M.D.**; Vice President and Chief Scientific Officer  
**Thomas F. Doyle, JD**; Vice President, Strategic Initiatives  
**Robert G. Pietrusko, Pharm.D.**; Vice President, Global Regulatory Affairs and Quality  
**Charles A. Rowland**; Vice President and Chief Financial Officer  
**Daniel B. Soland**; Vice President and Chief Operating Officer

### Board of Directors

**Vincent J. Milano**; Chairman  
**Frank Baldino, Jr., Ph.D.**; Chief Executive Officer and Chairman of the Board of Directors of Cephalon Inc.  
**Paul A. Brooke**; Managing Director and Co-Founder of venBio; managing member, PMSV Holdings LLC.  
**William D. Claypool, M.D.**; Senior Partner at Penmark Associates, LLC.  
**Michael Dougherty**; President and Chief Executive Officer, Adolor Corporation  
**Robert J. Glaser**; Senior Partner of Penmark Associates  
**John R. Leone**; Partner, Paul Capital Partners  
**Howard H. Pien**; Former President, Chief Executive Officer and Director, Medarex

Employees  
180 Employees (10/2009)

Ticker  
VPHM (Nasdaq Global Select Market)

### Our Vision

Our vision at ViroPharma as a multinational pharmaceutical company is to be recognized worldwide for developing and marketing innovative products addressing unmet medical needs. At ViroPharma, we strive to improve the lives of patients and to deliver medicines that address serious unmet medical needs. Our goal is simple in that we dedicate ourselves to developing and marketing products that help address dangerous, potentially life-threatening conditions including diseases such as hereditary angioedema (HAE) that are caused by C1 esterase inhibitor deficiency, and *C. difficile*. We focus our efforts on providing these medicines to physicians that treat and/or prevent serious diseases, and will expand on those franchises by capitalizing on business development. We will continue to focus on execution in all areas of our business. We will maintain our focus on building shareholder value. We will maintain our focus on the needs of patients, physicians and payers. And we will remain committed to quality and the continuous improvement of our performance, products and people.

Investor Inquiries

**William Roberts**; Vice President, Corporate Communications  
(610) 321-6288

**Robert Doody**; Investor Relations and Corporate Communications  
(610) 321-6290

Media Inquiries

**Kristina Broadbelt**; Public Relations and Advocacy  
(610) 321-2358

Business Development

**Clayton Fletcher**; Vice President , Business Development  
(610) 321-6789  
[clayton.fletcher@viropharma.com](mailto:clayton.fletcher@viropharma.com)